Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase ...

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last year. There are currently no approved vaccines to protect against ...